{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:52:15Z","timestamp":1784019135485,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Despite improvements in multiple myeloma (MM) survival rates, data on cardiovascular outcomes in long-term survivors remain lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective case\u2013control study utilized the Korean National Health Insurance Service database (2009\u20132020) to compare the incidence of cardiovascular disease (CVD) between patients with MM and a matched control group, focusing on long-term (&gt;\u20095\u00a0years) survivors. A preliminary case cohort (n\u2009=\u200915,402 patients with MM) and a matched control cohort (n\u2009=\u2009123,216 patients without MM) were established based on birth year and sex. Following 1:1 propensity score matching, the final matched cohorts each comprised 15,402 participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The case and control cohorts were comparable in mean age (66.2\u2009\u00b1\u200911.5\u00a0years vs. 66.1\u2009\u00b1\u200911.3\u00a0years), sex, age distribution, and comorbidities. By the 8-year follow-up, the cumulative incidence of CV events (12.5% vs. 22.1%) and CVD risk were significantly lower in the case cohort. The 5-year landmark analysis revealed significant differences in CVD incidence between the cohorts (7.8% [case cohort] vs. 9.8% [control cohort]), with variations across age groups and sex, highlighting a significantly higher CVD risk among patients aged\u2009&lt;\u200950\u00a0years in the case cohort (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings underscore the need for vigilant CVD monitoring in MM long-term survivors, particularly those aged\u2009&lt;\u200950\u00a0years at first diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implication for Cancer Survivors<\/jats:title>\n                    <jats:p>This study highlights the importance of integrating cardiovascular monitoring and risk management into long-term care for MM survivors, with a focus on younger patients and personalized interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10238-024-01368-2","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T05:01:53Z","timestamp":1718168513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Major cardiovascular events in long-term multiple myeloma survivors: a Korean case\u2013control study (the CAREMM-2105 study)"],"prefix":"10.1007","volume":"24","author":[{"given":"Jeonghoon","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seulji","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinseon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongyoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Hyun","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghoon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"key":"1368_CR1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"1368_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3322\/caac.21252","volume":"64","author":"G Bianchi","year":"2014","unstructured":"Bianchi G, Anderson KC. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64(6):422\u201344.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1368_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676\u201381.","journal-title":"Semin Oncol"},{"issue":"2","key":"1368_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4143\/crt.2021.291","volume":"53","author":"S Hong","year":"2021","unstructured":"Hong S, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53(2):301\u201315.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"1368_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"1368_CR6","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/ejh.12070","volume":"90","author":"S Moore","year":"2013","unstructured":"Moore S, et al. Weekly intravenous bortezomib is effective and well tolerated in relapsed\/refractory myeloma. Eur J Haematol. 2013;90(5):420\u20135.","journal-title":"Eur J Haematol"},{"key":"1368_CR7","doi-asserted-by":"crossref","unstructured":"Bringhen S et al. Cardiovascular adverse events in modern myeloma therapy\u2014Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica, 2018;103(9): 1422\u20131432.","DOI":"10.3324\/haematol.2018.191288"},{"issue":"4","key":"1368_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s44228-022-00017-3","volume":"4","author":"A Ibrahim","year":"2022","unstructured":"Ibrahim A, et al. Management of multiple myeloma in the middle east: unmet needs, challenges and perspective. Clin Hematol Int. 2022;4(4):127\u201332.","journal-title":"Clin Hematol Int"},{"issue":"3","key":"1368_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, et al. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9(3):26.","journal-title":"Blood Cancer J"},{"key":"1368_CR10","doi-asserted-by":"publisher","first-page":"204062072210867","DOI":"10.1177\/20406207221086755","volume":"13","author":"X Yin","year":"2022","unstructured":"Yin X, et al. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Ther Adv Hematol. 2022;13:20406207221086756.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"1368_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-023-00849-z","volume":"13","author":"J El-Cheikh","year":"2023","unstructured":"El-Cheikh J, et al. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies. Blood Cancer J. 2023;13(1):83.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1368_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"1368_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","volume":"21","author":"VG Patel","year":"2019","unstructured":"Patel VG, Cornell RF. Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management. Curr Oncol Rep. 2019;21(4):29.","journal-title":"Curr Oncol Rep"},{"issue":"10","key":"1368_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1368_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.4093\/dmj.2020.0207","volume":"44","author":"HK Kim","year":"2020","unstructured":"Kim HK, et al. Data configuration and publication trends for the Korean national health insurance and health insurance review & assessment database. Diabetes Metab J. 2020;44(5):671\u20138.","journal-title":"Diabetes Metab J"},{"issue":"5","key":"1368_CR16","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"1","key":"1368_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/bimj.200810488","volume":"51","author":"PC Austin","year":"2009","unstructured":"Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51(1):171\u201384.","journal-title":"Biom J"},{"issue":"22","key":"1368_CR18","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","volume":"107","author":"M Fontes Oliveira","year":"2021","unstructured":"Fontes Oliveira M, et al. Optimising cardiovascular care of patients with multiple myeloma. Heart. 2021;107(22):1774\u201382.","journal-title":"Heart"},{"issue":"9","key":"1368_CR19","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","volume":"133","author":"W Li","year":"2016","unstructured":"Li W, et al. Cardiovascular complications of novel multiple myeloma treatments. Circulation. 2016;133(9):908\u201312.","journal-title":"Circulation"},{"issue":"13","key":"1368_CR20","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23(13):2900\u20132.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1368_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12185-008-0139-7","volume":"88","author":"A Hacihanefioglu","year":"2008","unstructured":"Hacihanefioglu A, Tarkun P, Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. Int J Hematol. 2008;88(2):219\u201322.","journal-title":"Int J Hematol"},{"issue":"9983","key":"1368_CR22","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385(9983):2197\u2013208.","journal-title":"Lancet"},{"issue":"4","key":"1368_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000442511","volume":"1","author":"P Yadav","year":"2016","unstructured":"Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Dis. 2016;1(4):241\u201357.","journal-title":"Kidney Dis"},{"issue":"2","key":"1368_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/annonc\/mdw604","volume":"28","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky NG, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400\u20137.","journal-title":"Ann Oncol"},{"issue":"28","key":"1368_CR25","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2014.60.3654","volume":"33","author":"C Fung","year":"2015","unstructured":"Fung C, et al. Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol. 2015;33(28):3105\u201315.","journal-title":"J Clin Oncol"},{"issue":"23","key":"1368_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029967","volume":"12","author":"Y Gon","year":"2023","unstructured":"Gon Y, et al. Heart disease mortality in cancer survivors: a population-based study in Japan. J Am Heart Assoc. 2023;12(23): e029967.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"1368_CR27","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1001\/jamacardio.2016.3841","volume":"2","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2(1):88\u201393.","journal-title":"JAMA Cardiol"},{"issue":"16","key":"1368_CR28","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMc1209012","volume":"367","author":"M Voskoboynik","year":"2012","unstructured":"Voskoboynik M, Urban D, Mileshkin L. Early cardiovascular death in patients with cancer. N Engl J Med. 2012;367(16):1572\u20133.","journal-title":"N Engl J Med"},{"key":"1368_CR29","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1182\/blood-2018-99-117959","volume":"132","author":"AS Rosenberg","year":"2018","unstructured":"Rosenberg AS, et al. Changing incidence of major cardiovascular events in multiple myeloma patients over time. Blood. 2018;132:3598.","journal-title":"Blood"},{"issue":"3","key":"1368_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","volume":"208","author":"JL Gnerlich","year":"2009","unstructured":"Gnerlich JL, et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341\u20137.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"1368_CR31","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(19)30800-9","volume":"21","author":"E Suh","year":"2020","unstructured":"Suh E, et al. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the childhood cancer survivor study. Lancet Oncol. 2020;21(3):421\u201335.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1368_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1470-2045(19)30858-7","volume":"21","author":"P L\u00e4hteenm\u00e4ki","year":"2020","unstructured":"L\u00e4hteenm\u00e4ki P. Late morbidity and mortality in young survivors of cancer. Lancet Oncol. 2020;21(3):327\u20139.","journal-title":"Lancet Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-024-01368-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-024-01368-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:20:36Z","timestamp":1732969236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-024-01368-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1368"],"URL":"https:\/\/doi.org\/10.1007\/s10238-024-01368-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4191924\/v1","asserted-by":"object"}]},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"125"}}